A5079163416- Glioma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Hepatocellular Carcinoma Treatment and Prognosis
- Adrenal and Paraganglionic Tumors
- Radiomics and Machine Learning in Medical Imaging
- Microtubule and mitosis dynamics
- Brain Metastases and Treatment
- Neurofibromatosis and Schwannoma Cases
- Lung Cancer Research Studies
- Sarcoma Diagnosis and Treatment
- Ultrasound and Hyperthermia Applications
- Advanced Radiotherapy Techniques
- Radiation Therapy and Dosimetry
- MRI in cancer diagnosis
- Protein Degradation and Inhibitors
- Cancer Immunotherapy and Biomarkers
- Ubiquitin and proteasome pathways
- Medical Imaging Techniques and Applications
- Brain Tumor Detection and Classification
Johns Hopkins Hospital
2022-2024
Oregon Health & Science University
2024
Johns Hopkins Medicine
2023
Johns Hopkins University
2023
National Institutes of Health
2023
National Cancer Institute
2023
Abstract Purpose: Isocitrate dehydrogenase (IDH)-mutant gliomas are usually treated with radiotherapy and chemotherapy, which increases the risk for neurocognitive sequelae during patients’ most productive years. We report our experience using off-label first-in-class mutant IDH1 inhibitor ivosidenib its impact on tumor volume in IDH-mutant gliomas. Experimental Design: retrospectively analyzed patients ages ≥18 years radiation/chemotherapy-naïve, IDH1, nonenhancing, radiographically active,...
Abstract A significant challenge in brain metastases (BM) management is distinguishing radiation-induced treatment effect (TE) from tumor recurrence (TR). TE mimics the appearance of TR on follow-up MRI, making radiographic diagnosis unreliable. The standardized Response Assessment Neuro-Oncology for (RANO-BM) suboptimal due to high inter-reader variability. We compared performance artificial intelligence (AI)-driven MRI features with that RANO-BM criteria differentiating TR. hypothesize...
<div>Abstract<p>Purpose: Isocitrate dehydrogenase (IDH) mutant gliomas are usually treated with radiotherapy and chemotherapy, which increases the risk for neurocognitive sequelae during patients’ most productive years. We report our experience using off-label first-inclass IDH1mut-inhibitor ivosidenib its impact on tumor volume in IDHmut gliomas. Experimental Design: retrospectively analyzed patients aged ≥18 years radiation/chemotherapy-naïve, IDH1mut, non-enhancing,...
Abstract Proton radiotherapy (PRT) has superior physical dose distribution with a lesser integral off target radiation exposure compared standard photon resulting in reduced toxicity of uninvolved normal tissues. However, there may be areas targeted for high treatment as result uncertainty about the relative radiobiologic effect (RBE) proton and potential localized doses at end beam range (Bragg peak). This radiation-induced contrast enhancement (RICE) reflecting transient or permanent...
Abstract Following radiation therapy, a significant challenge in brain metastases (BM) management is differentiating radiation-induced-treatment effect (TrE) from tumor recurrence (TuR). TrE can be indistinguishable TuR using conventional MRI. Advanced imaging techniques (e.g., perfusion MRI, PET/MRI) are not consistently used, and the standardized Response Assessment Neuro-Oncology for (RANO-BM) sensitive to inter-reader variability. The performance of an artificial intelligence (AI)-driven...
Abstract Radiation Therapy affects a wide range of circulating lymphocyte subpopulations that are integral to mounting successful lymphocyte-mediated immune response. Lymphopenia is associated with inferior tumor control and could be addressed improve outcomes in glioblastoma. RT one significant potentially actionable iatrogenic suppressor response may limit the success therapy. We hypothesized comprehensive evaluation serial cytokine measurements during concurrent radiation chemotherapy...
<div>Abstract<p>Purpose: Isocitrate dehydrogenase (IDH) mutant gliomas are usually treated with radiotherapy and chemotherapy, which increases the risk for neurocognitive sequelae during patients’ most productive years. We report our experience using off-label first-inclass IDH1mut-inhibitor ivosidenib its impact on tumor volume in IDHmut gliomas. Experimental Design: retrospectively analyzed patients aged ≥18 years radiation/chemotherapy-naïve, IDH1mut, non-enhancing,...
<div>AbstractPurpose:<p>Isocitrate dehydrogenase (IDH)-mutant gliomas are usually treated with radiotherapy and chemotherapy, which increases the risk for neurocognitive sequelae during patients’ most productive years. We report our experience using off-label first-in-class mutant IDH1 inhibitor ivosidenib its impact on tumor volume in IDH-mutant gliomas.</p>Experimental Design:<p>We retrospectively analyzed patients ages ≥18 years radiation/chemotherapy-naïve, IDH1,...
<div>AbstractPurpose:<p>Isocitrate dehydrogenase (IDH)-mutant gliomas are usually treated with radiotherapy and chemotherapy, which increases the risk for neurocognitive sequelae during patients’ most productive years. We report our experience using off-label first-in-class mutant IDH1 inhibitor ivosidenib its impact on tumor volume in IDH-mutant gliomas.</p>Experimental Design:<p>We retrospectively analyzed patients ages ≥18 years radiation/chemotherapy-naïve, IDH1,...
2063 Background: Isocitrate Dehydrogenase (IDH) mutant gliomas represent a distinct class of primary brain tumors. Mutant IDH is driver mutation implicated in gliomagenesis and potential therapeutic target. Ivosidenib, an inhibitor IDH1, currently being evaluated to treat gliomas. In the present study we assess our single-institutional experience with off-label use ivosidenib reduce tumor growth rate patients Methods: We have longitudinally analyzed imaging histology-proven radio-...
Abstract BACKGROUND As clinical trials are ongoing to establish the role of IDH inhibitors in treatment lower-grade gliomas, long-term data is not yet available. Hence, here we share our real-world experience with off-label ivosidenib. METHODS In this single-institution retrospective analysis, included chemo/radiotherapy-naïve, gadolinium non-enhancing WHO Grade 2/3 IDH1-mutated astrocytomas (AS) and oligodendrogliomas (OG) that were treated ivosidenib for ≥ 5 months active tumor growth. We...